Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated

Tango Therapeutics, Inc.

2025-Q2 EPS reported -$0.71 vs consensus -$0.35 ▼ miss (-100.1%)

Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.
Cash $180.8M; expects to fund operations into Q1 2027.
Gilead collaboration research term trimmed from 7 to 5 yrs; $53.8M deferred revenue to be recognized in Q3 2025.
First patients dosed in TNG462 combo with Revolution Medicines RAS(ON) inhibitors and TNG456 Phase 1/2.
TNG462 monotherapy data expected 2H 2025; TNG260 clinical data also expected 2H 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.